1260527-40-9

Basic information

• Product Name: (+/-)methyl 2-(6-azaspiro[2.5]octan-5-ylmethylamino)-5-chlorobenzoate
• Synonyms: (+/-)methyl 2-(6-azaspiro[2.5]octan-5-ylmethylamino)-5-chlorobenzoate
• CAS NO: 1260527-40-9
• Molecular Weight: 308.808
• Mol File: 1260527-40-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (+/-)methyl 2-(6-azaspiro[2.5]octan-5-ylmethylamino)-5-chlorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)methyl 2-(6-azaspiro[2.5]octan-5-ylmethylamino)-5-chlorobenzoate(1260527-40-9)
• EPA Substance Registry System: (+/-)methyl 2-(6-azaspiro[2.5]octan-5-ylmethylamino)-5-chlorobenzoate(1260527-40-9)

Safety Data

• Hazardous Substances Data: 1260527-40-9(Hazardous Substances Data)

Upstream product

• 5202-89-1 4-chlorobenzenesulfonyl chloride 
• 1260527-33-0 (+/-) tert-butyl 5-formyl-6-azaspiro[2.5]octane-6-carboxylate 
• 1260527-32-9 6-azaspiro[2.5]octane hydrobromide 
• 1037834-61-9 N-cbz-6-azaspiro[2.5]octane 
• 955028-67-8 tert-butyl 6-azaspiro[2.5]octane-6-carboxylate 

Downstream Products

• 1260527-49-8 (+/-)-methyl 5-chloro-2-((6-(5-(4-fluorophenyl)-2-methylthiazole-4-carbonyl)-6-azaspiro[2.5]octan-5-yl)methylamino)benzoate 

Relevant articles and documents

SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION

The invention concerns a spiro-amino compound of Formula (Vl) wherein m is 1 or 2 or 3, n is 1 or 2, R is selected from a 5- or 6-membered aromatic ring and a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O e N, such ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, halogen, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl, phenyl optionally substituted with one or more halogen atoms, a 5- or 6-membered heterocycle comprising at least one nitrogen atom; P is a substituent Q or COQ, wherein Q is selected from the group consisting of phenyl, pyridil, pyrimidil, quinolyl, isoquinolyl, quinoxalyl, benzofuranyl, imidazotriazolyl, being such Q optionally substituted with one or more substituents selected from the group consisting of (C1-C3)alkyl, halogen, trifluoromethyl, carbammido, methylcarbammido, carboxy, methylcarboxy or a pharmaceutically acceptable salt thereof.